How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Angiotensin II (drug), Vasopressin (drug), Norepinephrine (drug)
How long the study runs: Study runs about 30 months (dates as stated)
About the drug or intervention: Angiotensin II — drug: Angiotensin II infusion · Vasopressin — drug: Vasopressin infusion · Norepinephrine — drug: Standard care vasopressor therapy, norepinephrine infusion
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 18 Years and over
Who: All
Number of participants: 45
Started: 2024-01-05
Last checked: 2025-03

Plain English Summary

What is this study?

• Testing a new treatment for septic shock
• NA - 45 participants
• Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk

Who can take part?

• Ages 18 Years and over
• Diagnosed with septic shock

Where?

• London - King's College Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.

Septic ShockAcute Kidney Injury

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 18 Years and over
Who can join: All genders

What the study is looking for

✓Within 48 hours of intensive care admission
✓Evidence of suspected or confirmed infection
✓Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures)
✓Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min
✓Lactate \>2mmol/L at any stage prior to randomisation

Who cannot take part

✗Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II
✗Patients receiving other vasoactive drugs in addition to norepinephrine
✗Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min)
✗Patients receiving extra corporal membrane oxygenation (ECMO)
✗Patients with acute occlusive coronary syndromes requiring intervention

See the full criteria

Inclusion Criteria: * Within 48 hours of intensive care admission * Evidence of suspected or confirmed infection * Sequential Organ Failure (SOFA) score increase of 2 or more (assuming a baseline of 0 if no previous measures) * Requirement for norepinephrine infusion as the sole vasopressor agent in a dose of \>0.1mcg/kg/min * Lactate \>2mmol/L at any stage prior to randomisation Exclusion Criteria: * Known intolerance to Sonovue™ contrast medium, vasopressin or angiotensin II * Patients receiving other vasoactive drugs in addition to norepinephrine * Patients with known chronic kidney disease (CKD) stage 4 or 5 (baseline glomerular filtration rate (GFR) \<30mls/min) * Patients receiving extra corporal membrane oxygenation (ECMO) * Patients with acute occlusive coronary syndromes requiring intervention * Patients with mesenteric ischaemia * Patients with a history or presence of aortic dissection or abdominal aortic aneurysm * Patients with Raynaud's syndrome or acute vaso-occlusive conditions * Pregnancy

Where Is This Study? (1 UK site)

King's College Hospital

London SE5 9RS, United Kingdom

Recruiting

Site contact (verified)

Sam Hutchings02032994957 sam.hutchings@nhs.net

How to Get in Touch

Sam Hutchings

Sponsor contact

CONTACT

02032994957 sam.hutchings@nhs.net

Data sourced from ClinicalTrials.gov · Last verified: 2025-03